DRIO
DarioHealth Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
6.75
PEG
0.00
P/B
6.14
P/S
2.74
EV/EBITDA
-1.82
DCF Value
$-5.99
FCF Yield
-42.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
56.6%
Operating Margin
-163.9%
Net Margin
276.1%
ROE
88.0%
ROA
168.1%
ROIC
-36.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.2M | $86.0M | $1.90 |
| FY 2025 | $22.4M | $-41.7M | $1.24 |
| Q3 2025 | $5.0M | $-2.1M | $0.38 |
| Q2 2025 | $5.4M | $-13.0M | $-0.20 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.28
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.